Nikkei with the report that biotech venture AnGes will ready production capacity for 1 million doses of COVID19 vaccines by March They also say, and this is key (!):
<ul><li>There is more policy lag in the pipeline from past hikes</li></ul><p>The market isn't pricing in any further ECB hikes.</p> This article was written by
Leave a Comment